Core Scientific (CORZ) is higher today after investors digested a recent SEC filing detailing a major expansion of its delayed-draw bridge credit agreement. The company increased total term-loan commitments by $500.0 million, bringing the facility to $1.0 billion, and borrowed the full incremental amount on the March 18, 2026 closing date.

The amendment was executed as Amendment No. 1 to the Delayed-Draw Bridge Credit Agreement, naming Morgan Stanley Senior Funding as administrative and collateral agent and JPMorgan Chase Bank as the amendment term lender. The added commitment was made under the facility’s accordion feature, effectively increasing available capital in one step and immediately boosting gross liquidity via the full draw.

The added borrowing capacity is being viewed as an execution enabler for Core Scientific’s infrastructure strategy, particularly its push toward AI/HPC-focused data-center colocation. In the near term, the financing reduces funding uncertainty around buildout timing, but it also raises questions about the company’s interest burden, leverage trajectory, and eventual takeout/refinancing strategy for a bridge structure.

Investors will likely track follow-on disclosures about how the proceeds are allocated across sites and capacity additions, plus any updates on longer-term capital structure plans that could replace bridge debt with term financing. The next major catalyst on the calendar is the company’s next quarterly earnings report, where management commentary on capex pacing, customer contracting, and AI/HPC ramp timing could determine whether today’s move has follow-through.